Slingshot members are tracking this event:

Novartis' (NVS) PKC412 for Newly-Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) Designated Breakthrough Therapy by FDA

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Pkc412, Newly-diagnosed, Flt3-mutated Acute Myeloid Leukemia, Fda, Breakthrough Therapy Designation